ImmunityBio, Inc.’s Anktiva shows promise for bladder cancer, but faces FDA setbacks and a rocky approval path. Peak sales for Anktiva’s indications could reach $900 million by 2028, implying a 73% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback